Mechanism-of-action determination of GMP synthase inhibitors and target validation in Candida albicans and Aspergillus fumigatus |
| |
Authors: | Rodriguez-Suarez Roberto Xu Deming Veillette Karynn Davison John Sillaots Susan Kauffman Sarah Hu Wenqi Bowman Joel Martel Nick Trosok Steve Wang Hao Zhang Li Huang Li-Yin Li Yang Rahkhoodaee Fariba Ransom Tara Gauvin Daniel Douglas Cameron Youngman Phil Becker Jeff Jiang Bo Roemer Terry |
| |
Institution: | Center of Fungal Genetics, Merck Frosst Canada, Montreal, Quebec H2X 3Y8, Canada. |
| |
Abstract: | Mechanism-of-action (MOA) studies of bioactive compounds are fundamental to drug discovery. However, in vitro studies alone may not recapitulate a compound's MOA in whole cells. Here, we apply a chemogenomics approach in Candida albicans to evaluate compounds affecting purine metabolism. They include the IMP dehydrogenase inhibitors mycophenolic acid and mizoribine and the previously reported GMP synthase inhibitors acivicin and 6-diazo-5-oxo-L-norleucine (DON). We report important aspects of their whole-cell activity, including their primary target, off-target activity, and drug metabolism. Further, we describe ECC1385, an inhibitor of GMP synthase, and provide biochemical and genetic evidence supporting its MOA to be distinct from acivicin or DON. Importantly, GMP synthase activity is conditionally essential in C. albicans and Aspergillus fumigatus and is required for virulence of both pathogens, thus constituting an unexpected antifungal target. |
| |
Keywords: | |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|